Bizarre Patents
A gun that fires a missile, powered by gas "discharged by the operator of the toy."
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6924267 | Methods and active substances for protecting organs The present invention comprises a method of protecting organs or tissue susceptible to reperfusion-induced dysfunction after ischemia. The method comprises parenterally administering to a patient a therapeutical composition containing natural alpha-1 acid glycoprote... | 08/02/2005 |
| 6902739 | Methods for treating joint inflammation, pain, and loss of mobility This invention provides methods and formulations for treating an inflammatory disease or reducing an inflammatory reaction comprising administering a fortified formulation comprising stabilized rice bran derivative and a fortification agent. Preferred rice bran deri... | 06/07/2005 |
| 6525176 | Purification of alpha-1 proteinase inhibitor A method for purifying human or other alpha-l proteinase inhibitor (댑 -PI) from a solution (which may be derived from the milk of a transgenic animal expressing the 댑 -PI) which comprises contacting the solution with a ... | 02/25/2003 |
| 6451542 | Methods and systems for diagnosing Kawasaki disease The invention provides a method for diagnosing Kawaski Disease (KD) in a patient suspected of suffering from KD by using as an index a ratio of the level (by weight/volume, w/v) of haptoglobin (Hp) to the level (by weight/volume, w/v) of apolipoprotein A1... | 09/17/2002 |
| 6441145 | Transgenically produced Antithrombin III This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fuco... | 08/27/2002 |
| 6153192 | Peptides with a characteristic antigenic determinant of 댑-microglobulin A peptide according to the present invention is not more than 40 amino acids long and contains a sequence which is at least 6 amino acids long from the amino acid partial sequence between the amino acids 144 and 183 of human 댑-microglobulin or/and ... | 11/28/2000 |
| 6093804 | Method for purification of alpha-1 proteinase inhibitor The methods of the present invention provide a simple means for separating active and inactive Alpha Proteinase Inhibitor (API). The methods further provide means for purifying API at high yield (>70%), and at levels of purity (>90%) and activity (>90%) n... | 07/25/2000 |
| 5981715 | Process for increasing the yield of a protein which has been subjected to viral inactivation The present invention is directed to a process for purifying alpha-1-PI. The process comprises providing an impure protein fraction which comprises alpha-1-PI. The impure protein fraction is suspended in an aqueous solution at pH 6. Insoluble proteins are... | 11/09/1999 |
| 5843705 | Transgenically produced antithrombin III This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fuco... | 12/01/1998 |
| 5817765 | Purification of plasma proteins Virus inactivating chemicals and/or detergents in an aqueous composition containing a water-soluble plasma protein are reduced by selecting a suitable combination of temperature and concentration above 0.5M of salt with a high salting out effect according... | 10/06/1998 |
| 5616693 | Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste The present invention is directed to a process for purifying alpha-1-PI. The process comprises providing an impure protein fraction which comprises alpha-1-PI. The impure protein fraction is suspended in an aqueous solution at pH 6. Insoluble proteins are... | 04/01/1997 |
| 5610285 | Purification of -1 proteinase inhibitor using novel chromatographic separation conditions Cation chromatography with solutions at pH less than 6.0 and low ionic strength can be utilized to purify human -1 proteinase inhibitor (-1 PI) from biological fluids including plasma and plasma fractions. The cation chromatography takes adv... | 03/11/1997 |
| 5492889 | Treatment of mast cell tumors There is provided a method for treating tumors in mammals by the administration of alpha 1-antitrypsin alone or in combination with other protease inhibitors.... | 02/20/1996 |
| 5420105 | Polymeric carriers for non-covalent drug conjugation Polymeric carriers are polypeptides comprising at least one drug-binding domain that non-covalently binds a drug. A polymeric carrier may be attached to an antibody specific for desired target cells to form immunoconjugates that deliver a drug to the targ... | 05/30/1995 |
| 5252713 | Polymeric carriers for non-covalent drug conjugation Polymeric carriers are polypeptides comprising at least one drug-binding domain that non-covalently binds a drug. A polymeric carrier may be attached to an antibody specific for desired target cells to form immunoconjugates that deliver a drug to the targ... | 10/12/1993 |
| 5151266 | Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies Methods are disclosed for increasing the solubility of antibodies and their radioisotope, toxin, or drug immunoconjugates and for reducing the non-specific uptake of antibody, either conjugated or unconjugated, into the RES organs such as via Fc receptor-... | 09/29/1992 |
| 5138034 | Method of fractionating plasma proteins A method of fractionating plasma protein which comprises treating a plasma protein-containing material in the following sequence of steps, provided that steps (ii) through (v) may be performed in an optional order: (i) freeze-thaw treatment, (ii) treatmen... | 08/11/1992 |
| 5134119 | Treatment of inflammation using 358 substituted alpha-antitrypsin A method for the prophylaxis or direct treatment of mast cell implicated skin inflammation in a patient which comprises topically administering an effective amount of an analog of alpha 1-antitrypsin, its salts or derivatives, and compositions thereof.... | 07/28/1992 |
| 5108987 | Conjugates of proteins with anti-tumor agents Conjugates of transferrin or ceruloplasmin with anti-tumour agents. Such conjugates are useful in the treatment of tumours. Suitable anti-tumour agents include adriamycin, daunomycin, methotrexate, vincristin, 6-mercaptopurine, cytosine arabinoside and cy... | 04/28/1992 |
| 5097019 | Pharmaceutical containing tissue protein PP4, a process for the preparation of PP4 and for the pasteurization thereof, and the use of PP4 An agent for the therapy or prophylaxis of disturbances of hemostasis, which contains tissue protein PP4, a process for the purification of PP4 by means of a hydrophobic adsorbent which is insoluble in water, and a process for the pasteurization of a solu... | 03/17/1992 |
| 5091177 | Monoclonal antibodies for treatment of human non-small cell lung carcinomas The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. The antibodies bind to normal human cells to a much le... | 02/25/1992 |
| 5073487 | Rapid assay for functional human 1 -proteinase inhibitor A simple, rapid and reliable assay for measuring functional enzyme inhibitor levels in body fluids and tissues, especially functional 댑 -proteinase inhibitor levels in human plasma or serum. 댒 -Macroglobulin is first in... | 12/17/1991 |
| 5053492 | Immunopurification using monoclonal antibodies to Mojave toxin Monoclonal antibodies to Mojave toxin and use for isolation of cross-reacting proteins in Crotalus venoms are disclosed. Hybridomas secreting monoclonal antibodies against Mojave toxin were established. The antibodies were used for identifying cross-react... | 10/01/1991 |
| 5051371 | Modified ଲ2 -microglobulin Substantially pure modified 댢 -microglobulin (m댢 m) of the formula I ##STR1## wherein R1 is 24-amino acid residue, with the sequence Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr-Ser-Arg-His-Pro-Ala-Glu-Asn-Gl... | 09/24/1991 |
| 5047509 | Abnormally glycosylated variants of a2 macroglobulin Noval abnormally glycosylated a2 -macroglobulins have been found in sera of patients suffering from autoimmune diseases. Such abnormally glycosylated materials have been isolated. The presence of these abnormally glycosylated materials in a pat... | 09/10/1991 |
| 4990597 | Process for the purification of placental tissue protein PP4 A process for the purification of tissue protein PP4 which can be obtained from placenta is described. This process makes use of the property of binding to saccharide polysulfates or to sulfated sugars in the presence of calcium ions.... | 02/05/1991 |
| 4886780 | Conjugates of apotransferrin proteins with anti-tumor agents Conjugates of transferrin or ceruloplasmin with anti-tumor agents. Such conjugates are useful in the treatment of tumors. Suitable anti-tumor agents include adriamycin, daunomycin, methotrexate, vincristin, 6-mercaptopurine, cytosine arabinoside and cyclo... | 12/12/1989 |
| 4883784 | Human complement factors and their therapeutic use The administration of Factor I and/or Factor H to a mammal has been found to alleviate or prevent such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis and glomerulonephritis.... | 11/28/1989 |
| 4842856 | Parenteral solution Parenteral solutions comprising (a) a sparingly soluble medicament active compound, (b) a solvent consisting of (i) 5-100 M/V % of an organic solvent or of a mixture of organic solvents and (ii) 0-95 W/V % of water, (c) A 0.5-30 W/V % strength aqueous solution of a... | 06/27/1989 |
| 4754019 | Method of producing substantially pure albumin using carboxylic acids and ammonium sulfate High purity albumin can be recovered in high yield from human plasma protein solution containing albumin by heat-treatment of the solution to denature and precipitate non-albumin proteins in a combination of specific conditions such as protein concentrati... | 06/28/1988 |
| 4740498 | Fibronectin preparations A fibronectin preparation in the form of an aqueous solution at least upon use is disclosed. The preparation contains at least one member selected from the group consisting of disaccharides, albumin and nonionic surface active agents as a stabilizer. The ... | 04/26/1988 |
| 4727027 | Photochemical decontamination treatment of whole blood or blood components Biological compositions are decontaminated by treatment with furocoumarin derivatives and irradiation under particular conditions in which the proteins retain their original physiological activities and any pathogenic microorganisms and polynucleotide fra... | 02/23/1988 |
| 4727059 | Fibronectin solution suitable for use in humans and process for its preparation A fibronectin injectable solution is made by recovering a fibronectin-containing raw material which is solubilized, provided with stabilizers and then subjected to an initial heat treatment at 57° to 60° for at least ten hours. After fibronectin concent... | 02/23/1988 |
| 4720385 | Protein compositions substantially free from infectious agents Compositions containing therapeutically or immunologically active proteins are rendered substantially free from infectious agents such as viable viruses and bacteria without substantial loss of therapeutic or immunologic activity by mixing the protein com... | 01/19/1988 |
| 4670544 | Process for the manufacture of the cold insoluble globulin and pharmaceutical preparation containing it What is disclosed is a method for isolating the cold insoluble globulin (CIG) from blood plasma concentrates containing factor VIII.... | 06/02/1987 |
| 4656254 | Method of preparing alpha-1-proteinase inhibitor and antithrombin III There is disclosed an improved method for separating one of alpha-1-proteinase inhibitor (also known as alpha-1 antitrypsin) and antithrombin-III from an aqueous solution of plasma proteins containing the same, such as from Cohn Fraction IV-1, Cohn Fracti... | 04/07/1987 |
| 4613501 | Inactivation of viruses in labile blood derivatives There is disclosed a process for obtaining a protein-containing composition which is substantially free of lipid-containing viruses without incurring substantial protein denaturation comprising contacting said protein-containing composition with an effect... | 09/23/1986 |
| 4587122 | Fibronectin-dextran-drug complex and method of preparation thereof The drug such as antitumor agents or antibiotics can preferentially be carried to a morbid part, for example, injured tissue and tumor site by administering its complex with fibronectin combined through an oxidized dextran to repair the morbid part. The c... | 05/06/1986 |
| 4565651 | Method of lyophilizing cold insoluble globulin A lyophylized cold insoluble globulin preparation can be prepared in stable condition and in short time by lyophylizing an aqueous solution of a cold insoluble globulin in the presence of albumin and a neutral amino acid, a monosaccharide, a disaccharide ... | 01/21/1986 |
| 4540573 | Undenatured virus-free biologically active protein derivatives A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid... | 09/10/1985 |
